(Q26771968)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

review article

0 references

title

Optimizing treatment success in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2 references

25 April 2019

30 June 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Nicola De Stefano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Filipe Palavra

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Tobias Derfuss

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Davorka Tomic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Tim Vollmer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sven Schippling

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Gavin Giovannoni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

24 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

3 references

25 April 2019

30 June 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

1053-1065

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

3 March 2020

copyright license

2 references

25 April 2019

on focus list of Wikimedia project

30 June 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Optimizing therapy early in multiple sclerosis: An evidence-based view

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Cause of death in patients attending multiple sclerosis clinics

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Axonal transection in the lesions of multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Clinical relevance of brain volume measures in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Magnetic resonance monitoring of lesion evolution in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Disease-specific molecular events in cortical multiple sclerosis lesions.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Thalamic atrophy is associated with development of clinically definite multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Placebo-controlled trial of oral laquinimod for multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Spanish consensus on the use of natalizumab (Tysabri(®))--2011.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Cost of disorders of the brain in Europe 2010.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Improving quality of life in multiple sclerosis: an unmet need.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Multiple sclerosis: current treatment algorithms.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Evidence for a two-stage disability progression in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Multiple sclerosis beyond EDSS: depression and fatigue

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Maximising therapeutic outcomes in patients failing on current therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Multiple sclerosis: an immune or neurodegenerative disorder?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Conventional MRI in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Brain atrophy in multiple sclerosis: what we know and would like to know

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Costs and quality of life of patients with multiple sclerosis in Europe

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

The measurement and clinical relevance of brain atrophy in multiple sclerosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Pathogenesis of tissue injury in MS lesions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Predictive value of early brain atrophy on response in patients treated with interferon β

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893374

Cognitive impairment in different MS subtypes and clinically isolated syndromes

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Social consequences of multiple sclerosis (1): early pension and temporary unemployment--a historical prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Quality of life among persons with multiple sclerosis and their caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Brain atrophy and lesion load predict long term disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Comparison of patient-reported outcome measures in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Defining and scoring response to IFN-β in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Scoring treatment response in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Refining response to treatment as defined by the Modified Rio Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7986-Y

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

12 December 2020

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a

1 reference

12 December 2020

Natural history of multiple sclerosis

1 reference

12 December 2020

Life expectancy in patients attending multiple sclerosis clinics

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters

1 reference

12 December 2020

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

1 reference

12 December 2020

Gray matter atrophy is related to long-term disability in multiple sclerosis

1 reference

12 December 2020

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing

1 reference

12 December 2020

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations.

1 reference

12 December 2020

10.1007/S00415-015-7986-Y

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 March 2020

1035869749

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

26705122

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26705122%20AND%20SRC:MED&resulttype=core&format=json